<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01348763</url>
  </required_header>
  <id_info>
    <org_study_id>MRV_DRV_PK</org_study_id>
    <secondary_id>2009-014924-42</secondary_id>
    <nct_id>NCT01348763</nct_id>
  </id_info>
  <brief_title>The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study</brief_title>
  <official_title>A Phase 1 Pharmacokinetic Study to Assess the Steady State Pharmacokinetic Profile and Short Term Safety of Maraviroc Dosed With Darunavir/Ritonavir All Once Daily, With and Without Nucleoside Analogues, in HIV-1 Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, open label, prospective, two phase pharmacokinetic study. Subjects
      currently attending for HIV care at St. Mary's Hospital, London will be eligible.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will describe the steady state pharmacokinetic parameters and short term safety of
      maraviroc/darunavir/ritonavir dosed at 150/800/100 mg once daily with and without
      tenofovir/emtricitabine 245/200 mg once daily in HIV-1 infected subjects.

      Fifteen HIV-1 infected subjects will be recruited. Eligible subjects will currently be
      receiving antiretroviral therapy comprising:

        -  tenofovir/emtricitabine 245/200 mg daily plus

        -  darunavir/ritonavir 800/100 mg daily

      On day 1, subjects will modify their current antiretroviral therapy to the following:

        -  tenofovir/emtricitabine 245/200 mg daily plus

        -  darunavir/ritonavir 800/100 mg daily plus

        -  maraviroc 150 mg daily On day 10 subjects will undergo an intensive pharmacokinetic
           visit.

      On day 11, subjects will modify their current antiretroviral therapy to the following:

        -  darunavir/ritonavir 800/100 mg daily plus

        -  maraviroc 150 mg daily (i.e. tenofovir/emtricitabine will be discontinued) On day 20
           subjects will undergo an intensive pharmacokinetic visit. Following completion of this
           study phase, subjects will recommence their usual antiretroviral treatment regimen and
           attend for a study follow up visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Ratio of the Maximum Plasma Concentration of Maraviroc Between 20 and 10 Day</measure>
    <time_frame>10 day, 20 days</time_frame>
    <description>On day 10 of the study the maximum concentractions of maraviroc will be measured . On day 20 of the study the maximum plasma concentractions maraviroc will be measured .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Changes in Haematology and Biochemistry Laboratory Tests</measure>
    <time_frame>35 days</time_frame>
    <description>Haematology and biochemistry laboratory tests such as full blood count, elelectrolytes and lipids will be measured to assess for changes.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Truvada, Darunavir/r and Maraviroc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be taking Truvada, Darunavir/r before entering the study. On day 1 they will add maraviroc then on day 11 they will stop the Truvada</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <description>Maraviroc 150 mg daily</description>
    <arm_group_label>Truvada, Darunavir/r and Maraviroc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada</intervention_name>
    <description>daily until 10. day then stop</description>
    <arm_group_label>Truvada, Darunavir/r and Maraviroc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>daily until 10. day then stop</description>
    <arm_group_label>Truvada, Darunavir/r and Maraviroc</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected males or females

          -  signed informed consent

          -  plasma HIV RNA &lt; 50 copies/mL at screening and on at least one other occasion over the
             last 3 months

          -  currently receiving an antiretroviral regimen comprising of: tenofovir 245 mg
             daily,emtricitabine 200 mg daily, darunavir 800 mg daily and ritonavir 100 mg daily

          -  no previous protease inhibitor resistance documented on HIV-1 genotypic resistance
             testing if an HIV resistance test available

          -  Between 18 to 65 years of age, inclusive

          -  subjects in good health upon medical history, physical exam, and laboratory testing

          -  BMI above or equal to 18 and below 32

          -  Female subjects who are heterosexually active and of childbearing potential (i.e., not
             surgically sterile or at least two years post menopausal) must practice contraception
             as follows from screening until 8 weeks after completion of the study:

          -  barrier contraceptives (condom OR diaphragm PLUS spermicide) or oral, implant or
             injectable hormonal contraceptive PLUS a barrier contraceptive or

          -  IUD /IUS PLUS a barrier contraceptive

          -  Female subjects of childbearing potential must have a negative urine pregnancy test.

          -  Male subjects who are heterosexually active must use two forms of barrier
             contraception (e.g., condom with spermicide) during heterosexual intercourse, from
             screening through completion of the study.

          -  Have no serologic evidence of active HBV infection evidenced by negative hepatitis B
             surface antigen and no serologic evidence of hepatitis C virus infection evidenced by
             a negative HCV antibody at screening.

          -  Have screening laboratory results (haematology and chemistry that fall within the
             normal range of the central laboratory's reference ranges unless the results have been
             determined by the Investigator to have no clinical significance

          -  CCR5 tropic HIV virus based on a genotypic tropism assay from either a stored plasma
             sample where available or fresh plasma

        Exclusion Criteria:

          -  current alcohol abuse or drug dependence

          -  positive urine drug of abuse screening

          -  pregnancy

          -  active opportunistic infection or significant co-morbidities

          -  current disallowed concomitant medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>male only</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Winston, MB BH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Mora-Peris B, Croucher A, Else LJ, Vera JH, Khoo S, Scullard G, Back D, Winston A. Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. J Antimicrob Chemother. 2013 Jun;68(6):1348-53. doi: 10.1093/jac/dkt006. Epub 2013 Jan 30.</citation>
    <PMID>23364475</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 25, 2011</study_first_submitted>
  <study_first_submitted_qc>May 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2011</study_first_posted>
  <results_first_submitted>September 10, 2019</results_first_submitted>
  <results_first_submitted_qc>October 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 31, 2019</results_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
    <mesh_term>Darunavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Truvada, Darunavir/r and Maraviroc</title>
          <description>Participants will be taking Truvada, Darunavir/r before entering the study. On day 1 they will add maraviroc then on day 11 they will stop the Truvada
Maraviroc: Maraviroc 150 mg daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>With Tenofovir/Emtricitabine (10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Without Tenofovir/Emtricitabine (11 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Truvada, Darunavir/r and Maraviroc</title>
          <description>Participants will be taking Truvada, Darunavir/r before entering the study. On day 1 they will add maraviroc then on day 11 they will stop the Truvada
Maraviroc: Maraviroc 150 mg daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Ratio of the Maximum Plasma Concentration of Maraviroc Between 20 and 10 Day</title>
        <description>On day 10 of the study the maximum concentractions of maraviroc will be measured . On day 20 of the study the maximum plasma concentractions maraviroc will be measured .</description>
        <time_frame>10 day, 20 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Truvada, Darunavir/r and Maraviroc</title>
            <description>Participants will be taking Truvada, Darunavir/r before entering the study. On day 1 they will add maraviroc then on day 11 they will stop the Truvada
Maraviroc: Maraviroc 150 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Ratio of the Maximum Plasma Concentration of Maraviroc Between 20 and 10 Day</title>
          <description>On day 10 of the study the maximum concentractions of maraviroc will be measured . On day 20 of the study the maximum plasma concentractions maraviroc will be measured .</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.79" upper_limit="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Changes in Haematology and Biochemistry Laboratory Tests</title>
        <description>Haematology and biochemistry laboratory tests such as full blood count, elelectrolytes and lipids will be measured to assess for changes.</description>
        <time_frame>35 days</time_frame>
        <population>No data reported</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada, Darunavir/r and Maraviroc</title>
            <description>Participants will be taking Truvada, Darunavir/r before entering the study. On day 1 they will add maraviroc then on day 11 they will stop the Truvada
Maraviroc: Maraviroc 150 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Changes in Haematology and Biochemistry Laboratory Tests</title>
          <description>Haematology and biochemistry laboratory tests such as full blood count, elelectrolytes and lipids will be measured to assess for changes.</description>
          <population>No data reported</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Truvada, Darunavir/r and Maraviroc</title>
          <description>Participants will be taking Truvada, Darunavir/r before entering the study. On day 1 they will add maraviroc then on day 11 they will stop the Truvada
Maraviroc: Maraviroc 150 mg daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alan Winston</name_or_title>
      <organization>Imperial College London</organization>
      <phone>+442033121603 ext 21603</phone>
      <email>a.winston@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

